Edwards Lifesciences Corp (EW)vsRLX Technology Inc (RLX)
EW
Edwards Lifesciences Corp
$79.96
-3.38%
HEALTHCARE · Cap: $47.71B
RLX
RLX Technology Inc
$2.10
-1.87%
CONSUMER DEFENSIVE · Cap: $2.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 74% more annual revenue ($6.30B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 17.4%. RLX trades at a lower P/E of 21.4x. RLX earns a higher WallStSmart Score of 68/100 (B-).
EW
Buy61
out of 100
Grade: C+
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.7%
Fair Value
$261.90
Current Price
$79.96
$181.94 discount
Margin of Safety
+60.3%
Fair Value
$6.14
Current Price
$2.10
$4.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
16.7% revenue growth
Reasonable price relative to book value
Revenue surging 46.8% year-over-year
Earnings expanding 81.7% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
ROE of 5.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
RLX carries more volatility with a beta of 1.15 — expect wider price swings.
RLX is growing revenue faster at 46.8% — sustainability is the question.
RLX generates stronger free cash flow (192M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RLX scores higher overall (68/100 vs 61/100), backed by strong 25.5% margins and 46.8% revenue growth. EW offers better value entry with a 69.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?